NRG Oncology
- Country
- ๐บ๐ธUnited States
- Ownership
- Private
- Established
- 2014-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.nrgoncology.org
Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-01-30
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 1300
- Registration Number
- NCT05705401
- Locations
- ๐บ๐ธ
Cedars-Sinai Cancer - Tarzana, Tarzana, California, United States
๐บ๐ธHealth Central, Ocoee, Florida, United States
๐บ๐ธNorthwestern Medicine Orland Park, Orland Park, Illinois, United States
Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-12-12
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 428
- Registration Number
- NCT05646316
- Locations
- ๐บ๐ธ
Fairview Southdale Hospital, Edina, Minnesota, United States
๐บ๐ธNorthwestern Medicine Cancer Center Warrenville, Warrenville, Illinois, United States
๐บ๐ธParkland Memorial Hospital, Dallas, Texas, United States
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer
- Conditions
- Interventions
- Drug: CarboplatinDrug: CisplatinProcedure: Computed TomographyBiological: DurvalumabDrug: EtoposideRadiation: Image Guided Radiation TherapyDrug: PaclitaxelDrug: PemetrexedProcedure: Positron Emission TomographyOther: Quality-of-Life AssessmentOther: Questionnaire AdministrationRadiation: Stereotactic Body Radiation Therapy
- First Posted Date
- 2022-11-22
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 474
- Registration Number
- NCT05624996
- Locations
- ๐บ๐ธ
UMass Memorial Medical Center - University Campus, Worcester, Massachusetts, United States
๐บ๐ธAscension Borgess Hospital, Kalamazoo, Michigan, United States
๐บ๐ธBenefis Sletten Cancer Institute, Great Falls, Montana, United States
Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases
- First Posted Date
- 2022-06-29
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 236
- Registration Number
- NCT05438212
- Locations
- ๐บ๐ธ
Kaiser Permanente-Anaheim, Anaheim, California, United States
๐บ๐ธSutter Auburn Faith Hospital, Auburn, California, United States
๐บ๐ธSutter Cancer Centers Radiation Oncology Services-Auburn, Auburn, California, United States
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) for Recurrent, Metastatic, or Unresectable HER2-Positive Salivary Gland Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-06-07
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 116
- Registration Number
- NCT05408845
- Locations
- ๐บ๐ธ
UCSF Medical Center-Mission Bay, San Francisco, California, United States
๐บ๐ธEmory University Hospital Midtown, Atlanta, Georgia, United States
๐บ๐ธUniversity of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Study
- Conditions
- Interventions
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 240
- Registration Number
- NCT05327686
- Locations
- ๐บ๐ธ
University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
๐บ๐ธDayton Physicians LLC-Atrium, Franklin, Ohio, United States
๐บ๐ธMiami Valley Cancer Care and Infusion, Greenville, Ohio, United States
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
- Conditions
- Interventions
- First Posted Date
- 2021-12-30
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 1912
- Registration Number
- NCT05174169
- Locations
- ๐บ๐ธ
Harold Alfond Center for Cancer Care, Augusta, Maine, United States
๐บ๐ธMaineHealth/SMHC Cancer Care and Blood Disorders-Biddeford, Biddeford, Maine, United States
๐บ๐ธOchsner Medical Center Jefferson, New Orleans, Louisiana, United States
Testing the Addition of the Chemotherapy Drug Lomustine (Gleostineยฎ) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
- First Posted Date
- 2021-10-27
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 306
- Registration Number
- NCT05095376
- Locations
- ๐บ๐ธ
Fairbanks Memorial Hospital, Fairbanks, Alaska, United States
๐บ๐ธMercy Cancer Center - Carmichael, Carmichael, California, United States
๐บ๐ธJohn Muir Medical Center-Concord, Concord, California, United States
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
- Conditions
- Interventions
- First Posted Date
- 2021-10-18
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 9500
- Registration Number
- NCT05080673
- Locations
- ๐บ๐ธ
Saint John's Hospital - Healtheast, Maplewood, Minnesota, United States
๐บ๐ธMinnesota Oncology - Burnsville, Burnsville, Minnesota, United States
๐บ๐ธFairview Southdale Hospital, Edina, Minnesota, United States
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer
- First Posted Date
- 2021-09-22
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 260
- Registration Number
- NCT05053152
- Locations
- ๐บ๐ธ
Trinity Health Saint Joseph Mercy Oakland Hospital, Pontiac, Michigan, United States
๐บ๐ธCorewell Health William Beaumont University Hospital, Royal Oak, Michigan, United States
๐บ๐ธMunson Medical Center, Traverse City, Michigan, United States